Mydecine

Corporate brand

Mydecine is a United States- and Canada-oriented pharmaceutical company developing psychedelic and entactogenic drug candidates.

Last updated August 26, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Mydecine, also known as Mydecine Innovations Group, is a pharmaceutical company associated with the development of psychedelic and entactogenic medicines. Its research focus centers on compounds intended to address therapeutic areas in which altered states of consciousness, empathogenic effects, or related mechanisms may have clinical value. The company has worked with psilocybin-based candidates, synthetic tryptamines, and MDMA-like entactogens rather than operating primarily as a conventional consumer-facing pharmaceutical brand. The company’s publicly described pipeline has included several psilocybin and psilocin-related candidates. MYCO-001 and MYCO-003 are identified as psilocybin programs, while MYCO-004 is described as a patch-delivered tryptamine formulation. MYCO-005 is an aza psilocin analogue that the company positioned as having potentially improved safety characteristics. The pipeline has also included MDMA-like compounds: MYCO-002 was described as a potentially safer entactogen, while MYCO-006 and MYCO-007 were presented as short-acting candidates. Mydecine has additionally patented 5-BZT-MDMA and 6-BZT-MDMA, designated MY100 and MY101, respectively, as short-acting MDMA analogues. Public descriptions indicate that the structures of most of the company’s candidates were not disclosed. Mydecine has operated across the United States and Canada and has been associated with research, drug discovery, intellectual property, and the development of controlled-substance-based medicines. A notable regulatory and supply-chain milestone occurred in 2021, when the company made what was reported as the first legal import of magic mushrooms into Canada. This event reflected the practical regulatory complexity surrounding psychedelic research, including the lawful movement and handling of materials that remain controlled or restricted in many jurisdictions. The company also experienced financial pressure. In August 2022, reporting indicated that Mydecine faced financial difficulties and might cease operations. Subsequent funding allowed it to continue rather than shut down at that time. The available reference material does not establish the company’s current operating condition, financing position, clinical status, commercial revenue, or current leadership. It should therefore be treated as a specialized investigational pharmaceutical venture with an uncertain present status rather than as an established marketed-drug company.

History

Mydecine, formally referred to as Mydecine Innovations Group, developed as a pharmaceutical company focused on psychedelic and entactogenic medicines. Rather than building its identity around an approved commercial product, the company’s public profile has been defined by drug discovery, investigational compounds, intellectual property, and the regulatory work required to study controlled or restricted substances. Its research portfolio has included multiple psilocybin and tryptamine programs. MYCO-001 and MYCO-003 were described as psilocybin candidates. MYCO-004 represented an alternative-delivery approach, using a patch to deliver a tryptamine. MYCO-005 was described as a novel aza psilocin analogue that was intended to offer a potentially improved safety profile. These programs illustrate the company’s interest in modifying either the pharmacology or delivery method of psychedelic substances rather than limiting development to naturally occurring compounds in their unaltered form. Mydecine also pursued entactogens related to MDMA. MYCO-002 was presented as a potentially safer MDMA-like candidate, while MYCO-006 and MYCO-007 were described as short-acting compounds. The company patented two additional short-acting MDMA analogues, 5-BZT-MDMA and 6-BZT-MDMA, using the internal designations MY100 and MY101. Publicly available descriptions stated that the chemical structures of most candidates were not disclosed, limiting independent assessment of the full pipeline from the information summarized in the reference material. A significant operational milestone came in 2021, when Mydecine was reported to have made the first legal import of magic mushrooms into Canada. The event was notable because psychedelic drug development depends on compliance with controlled-substance rules, import permissions, secure handling, and documentation. It also reflected the company’s cross-border orientation, with activities associated with both Canada and the United States. The company later encountered financial pressure. In August 2022, reports said that Mydecine might cease operations because of financial difficulties. It obtained further funding and continued rather than shutting down at that point. The available material does not provide sufficient information to establish later financing rounds, clinical-trial outcomes, regulatory approvals, revenue, commercial launches, current headquarters, or current executives. Consequently, the historical record supports describing Mydecine as an investigational psychedelic-pharmaceutical developer, while its present corporate status remains uncertain.

2022
Additional funding supports continued operations
[1]Mydecineen.wikipedia.org
After reports that financial difficulties could force the company to cease operations, Mydecine obtained additional funding and did not shut down at that time.
2021
Reported first legal import of magic mushrooms into Canada
[1]Mydecineen.wikipedia.org
Mydecine was reported to have completed the first legal import of magic mushrooms into Canada, supporting its work with psychedelic research materials under applicable regulatory controls.

Products and positioning

An investigational pharmaceutical developer focused on psychedelic and entactogenic compounds, including potentially safer, shorter-acting, or alternative-delivery medicines.

Psilocybin drug candidate
MYCO-001
MYCO-001 is one of Mydecine’s publicly identified psilocybin-based investigational candidates. The available reference material does not specify its clinical stage, target indication, formulation, study results, or regulatory status.
Psilocybin drug candidate
MYCO-003
MYCO-003 is described as another psilocybin candidate in Mydecine’s development pipeline. Publicly supplied information does not establish whether it entered human trials, received regulatory clearance, or progressed to a defined commercial development stage.
Patch-delivered tryptamine
MYCO-004
MYCO-004 is a tryptamine candidate designed for delivery through a patch. Its inclusion in the pipeline reflects an effort to investigate an alternative administration method for a psychedelic compound. Specific pharmacological, clinical, and regulatory details are not provided in the available source material.
Aza psilocin analogue
MYCO-005
MYCO-005 is described as a novel aza psilocin analogue that was positioned as potentially offering improved safety characteristics. The available material does not confirm its clinical performance, safety profile, indication, or stage of development.
MDMA-like entactogen
MYCO-002
MYCO-002 is an MDMA-like entactogenic candidate that Mydecine described as potentially safer than established compounds in the same broad class. No verified clinical results or approval information is supplied in the reference material.
Short-acting entactogen
MYCO-006
MYCO-006 is identified as a short-acting MDMA-like entactogen in Mydecine’s research pipeline. The intended therapeutic use, mechanism, disclosed structure, development stage, and clinical evidence are not specified in the available material.
Short-acting entactogen
MYCO-007
MYCO-007 is another short-acting MDMA-like entactogen identified by Mydecine. It remained a development-stage compound in the supplied description, with no confirmed commercial launch or regulatory approval.
Patented MDMA analogue
MY100
MY100 is Mydecine’s designation for 5-BZT-MDMA, a patented short-acting MDMA analogue. The reference material identifies the patent and internal code but does not provide confirmed clinical or commercial development information.
Patented MDMA analogue
MY101
MY101 is the internal designation for 6-BZT-MDMA, another patented short-acting MDMA analogue associated with Mydecine. Its development stage and therapeutic application are not established by the supplied sources.

Brand decisions

2022
Secure additional funding after financial distressStrategy
Background
Reports indicated that Mydecine faced financial difficulties and might cease operations.
Action taken
The company obtained additional funding and continued operations rather than shutting down at that time.
Aftermath
The funding allowed the company to avoid the reported immediate shutdown risk, although the available material does not establish its subsequent financial condition.
Source
2021
Advance regulated psychedelic research operations in CanadaStrategy
Background
Research involving psychedelic materials requires compliance with controlled-substance and import rules. Mydecine’s reported legal import of magic mushrooms into Canada demonstrated an operational focus on establishing lawful access to research materials.
Action taken
The company completed what was reported as the first legal import of magic mushrooms into Canada.
Aftermath
The import became a notable regulatory and logistics milestone associated with Mydecine’s psychedelic-drug development activities.
Source

Recent events

2023-04-03
Mydecine announces board departure and appointment[4]Mydecine宣布董事离任及任命finanznachrichten.de
Reported: 2023-04-03
Mydecine announced that Todd Heinzl resigned from its board and that Neil Stevenson-Moore was appointed as an independent director and audit committee member, effective April 3, 2023.
2021-02-03
Mydecine announces Michael Connolly's board resignation[5]Mydecine宣布Michael Connolly辞去董事职务investingnews.com
Reported: 2021-02-03
Mydecine announced Michael Connolly's resignation from its Board of Directors and said Josephine Wu replaced him on the board.
2021-02-03
Mydecine appoints Josephine Wu to its board[5]Mydecine宣布Michael Connolly辞去董事职务investingnews.com
Reported: 2021-02-03
Mydecine Innovations Group announced Josephine Wu's appointment to its Board of Directors.
2021-01-11
Mydecine appoints Gordon Neal to its board[6]Mydecine任命Gordon Neal为董事会成员investingnews.com
Reported: 2021-01-11
Mydecine announced that it appointed Gordon Neal to its board of directors.
2021-01-11
Mydecine names Dean Ditto chief financial officer[6]Mydecine任命Gordon Neal为董事会成员investingnews.com
Reported: 2021-01-11
Mydecine announced that Dean Ditto had joined the company as chief financial officer.
2021-01-05
Mydecine sponsors microdosing study at Macquarie University[7]Mydecine 赞助麦考瑞大学微剂量研究biospace.com
Reported: 2021-01-05
Mydecine announced that it is sponsoring a study titled “The neurocognitive effects of low dose psychoactive substances” at Macquarie University in Australia.
2020-12-10
Mydecine and Microdose partner on webinar series[8]Mydecine与Microdose合作推出网络研讨会系列finance.yahoo.com
Reported: 2020-12-10
Mydecine Innovations Group announced a partnership with Microdose Psychedelic Insights to present a free, three-part live video discussion series titled “Mydecine Speaker Series.”
2020-09-30
Mindleap launches its mental health mobile app[9]Mindleap 推出心理健康移动应用financialpost.com
Reported: 2020-09-30
Mindleap, a subsidiary of Mydecine Innovations Group, launched its mental health mobile application, which was available for download on iOS and Android on September 30, 2020.
2020-08-18
Mydecine announces licensed production and distribution capabilities for natural-source psilocybin[10]Mydecine 宣布具备获许可的天然来源裸盖菇素生产与分销能力biospace.com
Reported: 2020-08-18
Mydecine announced that it was the first organization to exercise its cGMP capabilities under a special license to legally produce, transfer, sell, and export pharmaceutical-grade psilocybin derived from whole-mushroom extraction.
2020-06-15
Mydecine establishes research agreement with Applied Pharmaceutical Innovation[11]Mydecine与Applied Pharmaceutical Innovation建立研究合作prnewswire.com
Reported: 2020-06-15
Mydecine announced a research division agreement with Applied Pharmaceutical Innovation, providing access to drug-development expertise, facilities and licenses for research and development.

Showing the 10 most recent.

Sources14 sources

Cite this profile: Cite the canonical profile. /brand-wiki/mydecine · Editorial policy · How profiles are compiled